STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Tharimmune, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Tharimmune, Inc. entered an at-the-market Sales Agreement to sell shares of common stock with an aggregate offering price of up to $64,910,161 under its existing Form S-3 shelf. Clear Street LLC and President Street Global LLC will act as sales agents.

The company filed a prospectus supplement on November 6, 2025. Sales may occur from time to time via at-the-market transactions, negotiated deals, or block trades, and neither party is obligated to sell; the program can be suspended or terminated upon notice. The agents will receive commissions of up to 3.00% of aggregate gross proceeds, and Tharimmune agreed to reimburse up to $75,000 of certain legal expenses, plus ongoing legal costs. The company also announced, via press release, the closing of a private placement.

Positive
  • None.
Negative
  • None.

Insights

THAR establishes a $64.9M ATM facility with 3% fees.

Tharimmune set up an at-the-market program allowing discretionary issuance of common stock for up to $64,910,161 in gross proceeds under its effective S-3. Clear Street and President Street Global serve as agents, with sales possible via at-the-market trades, negotiated transactions, or block trades.

Economics disclosed include agent commissions up to 3.00% and reimbursement of certain legal expenses up to $75,000, plus ongoing legal costs. The agreement permits suspension or termination upon notice, and neither the company nor agents are obligated to sell, so actual issuance depends on market conditions and company decisions.

The company filed a prospectus supplement on November 6, 2025. Actual proceeds, pricing, and dilution (if any) will depend on future sales activity, which the agreement permits but does not require.

false 0001861657 0001861657 2025-11-06 2025-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 6, 2025

 

THARIMMUNE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41210   84-2642541
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I. R. S. Employer
Identification No.)

 

34 Shrewsbury Ave., Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices, including zip code)

 

(732) 889-3111

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value   THAR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Material Definitive Agreement

 

On November 6, 2025, the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with Clear Street LLC and President Street Global LLC, as sales agents (the “Agents”) to sell shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $64,910,161 (the “ATM Shares”) from time to time, through an “at the market offering” (the “ATM Offering”) as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”).

 

On November 6, 2025, the Company filed a prospectus supplement with the Commission in connection with the ATM Offering (the “Prospectus Supplement”) under its existing shelf Registration Statement on Form S-3 (File No. 333-270684) (the “Registration Statement”) initially filed with the Commission on March 17, 2023 and declared effective on March 24, 2023, and the base prospectus contained therein.

 

Upon delivery of a placement notice, and subject to the terms and conditions of the Sales Agreement, the Agents may sell the ATM Shares by any method that is deemed an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act, or any other method permitted by law, which may include negotiated transactions or block trades. The Company may sell the ATM Shares through the Agents in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but neither it nor the Agents have an obligation to sell any of the ATM Shares in the ATM Offering. No assurance can be given that the Company will sell any ATM Shares under the Sales Agreement, or, if it does, as to the price or the amount of ATM Shares that it sells or the dates when such sales will take place. The Company or the Agents may suspend or terminate the ATM Offering upon notice to the other parties and subject to other conditions. The Agents will use commercially reasonable efforts to effect the sales consistent with their normal trading and sales practices.

 

The Company has agreed to pay the Agents’ commissions for their respective services in acting as agents in the sale of the ATM Shares in the amount of up to 3.00% of the aggregate gross proceeds it receives from the sale of the ATM Shares pursuant to the Sales Agreement. The Company has also agreed to provide the Agents with customary indemnification and contribution rights. In addition, the Company has agreed to reimburse certain legal expenses incurred by the Agents in connection with execution of the Sales Agreement in an amount up to $75,000, in addition to certain ongoing legal expenses.

 

The ATM Shares are registered pursuant to the Registration Statement and the base prospectus contained therein, and offerings for the ATM Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the ATM Shares, nor shall there be any offer, solicitation or sale of the ATM Shares in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state.

 

The description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to, to the full text of the Sales Agreement, a copy of which is filed herewith as Exhibit 1.1, and is incorporated herein by reference.

 

A copy of the opinion of Lucosky Brookman LLP relating to the validity of the ATM Shares that may be sold pursuant to the ATM Offering is filed herewith as Exhibit 5.1.

 

Item 8.01. Other Events.

 

On November 6, 2025, the Company issued a press release announcing the closing of its private placement offering. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number
  Description
1.1   Sales Agreement, dated as of November 6, 2025, among the Company and Clear Street LLC and President Street Global, LLC, as Agents
5.1   Opinion of Lucosky Brookman LLP
99.1   Press Release, dated November 6, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  THARIMMUNE, INC.
   
Date: November 6, 2025 By: /s/ Mark Wendland
    Mark Wendland
    Chief Executive Officer

 

 

 

FAQ

What did Tharimmune (THAR) announce in this 8-K?

Tharimmune entered an at-the-market Sales Agreement to sell common stock with an aggregate offering price of up to $64,910,161 under its existing S-3 shelf.

Who are the sales agents for Tharimmune’s ATM program?

The agents are Clear Street LLC and President Street Global LLC.

What commissions will the agents receive under the ATM?

The agents will receive commissions of up to 3.00% of aggregate gross proceeds from sales under the program.

What expenses will Tharimmune reimburse related to the ATM?

Tharimmune agreed to reimburse certain legal expenses up to $75,000, in addition to certain ongoing legal expenses.

Is Tharimmune required to sell shares under the ATM?

No. Neither the company nor the agents are obligated to sell any shares; the program may be suspended or terminated upon notice.

What filing supports the ATM offering?

A prospectus supplement dated November 6, 2025, under the company’s effective Form S-3 (File No. 333-270684).

Did Tharimmune disclose any other financing activity?

Yes. It issued a press release announcing the closing of a private placement and attached it as Exhibit 99.1.
Tharimmune Inc

NASDAQ:THAR

THAR Rankings

THAR Latest News

THAR Latest SEC Filings

THAR Stock Data

31.58M
5.03M
17.13%
1.5%
12.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
BRIDGEWATER